Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure

Journal of Hepatology

Volumn 58, Issue 5, 2013, Pages 883-889

  Pol, Stanislas ^a   Aerssens, Jeroen ^b   Zeuzem, Stefan ^c   Andreone, Pietro ^d   Lawitz, Eric J ^e   Roberts, Stuart ^f   Younossi, Zobair ^g   Foster, Graham R ^h   Focaccia, Roberto ⁱ   Horban, Andrzej ^j   Pockros, Paul J ^k   Van Heeswijk, Rolf P G ^b   De Meyer, Sandra ^b   Luo, Don ^l   Botfield, Martyn ^m   Beumont, Maria ^b   Picchio, Gaston ^l  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e Alamo Medical Research   (United States)

^f ALFRED HOSPITAL   (Australia)

^g INOVA FAIRFAX HOSPITAL   (United States)

^h QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

ⁱ Emilio Ribas Infectious Diseases Institute   (Brazil)

^j MEDICAL UNIVERSITY OF WARSAW   (Poland)

^k SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

^l JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^m VERTEX PHARMACEUTICALS   (United States)

more..

Author keywords

Direct acting antiviral; Hepatitis C virus; REALIZE; Response predictors

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; TELAPREVIR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TREATMENT FAILURE; FEMALE; GENETIC POLYMORPHISM; GENETIC SCREENING; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; POLYMORPHISM, GENETIC; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84876294731     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.12.023     Document Type: Article

References (24)

1. J.G. McHutchison, E.J. Lawitz, M.L. Shiffman, A.J. Muir, G.W. Galler, and J. McCone Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 2009 580 593
2. D.L. Thomas, C.L. Thio, M.P. Martin, Y. Qi, D. Ge, and C. O'Huigin Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 2009 798 801
3. H.L. Tillmann, A.J. Thompson, K. Patel, M. Wiese, H. Tenckhoff, and H.D. Nischalke A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice Gastroenterology 139 2010 1586 1592
4. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, and T.J. Urban Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
5. A.J. Thompson, A.J. Muir, M.S. Sulkowski, D. Ge, J. Fellay, and K.V. Shianna Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virological response in genotype 1 hepatitis C virus Gastroenterology 139 2010 120 129
6. A. Rauch, Z. Kutalik, P. Descombes, T. Cai, J. Di Iulio, and T. Mueller Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study Gastroenterology 138 2010 1338 1345
7. V. Suppiah, M. Moldovan, G. Ahlenstiel, T. Berg, M. Weltman, and M.L. Abate IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 2009 1100 1104
8. Y. Tanaka, N. Nishida, M. Sugiyama, M. Kurosaki, K. Matsuura, and N. Sakamoto Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 2009 1105 1109
9. N.I. Rallón, S. Naggie, J.M. Benito, J. Medrano, C. Restrepo, and D. Goldstein Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients AIDS 24 2010 F23 F29
10. C.M. Lange, D. Moradpour, A. Doehring, H.A. Lehr, B. Müllhaupt, and S. Bibert Impact of donor and recipient ILB rs12979860 genotypes on hepatitis C virus liver graft reinfection J Hepatol 55 2011 322 327
11. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, and S. Roberts Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
12. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, and S. Zeuzem Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
13. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
14. K.E. Sherman, S.L. Flamm, N.H. Afdhal, D.R. Nelson, M.S. Sulkowski, and G.T. Everson Response-guided telaprevir combination treatment for hepatitis C virus infection N Engl J Med 365 2011 1014 1024
15. F. Poordad, J. McCone Jr, B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
16. S. Zeuzem, M.S. Sulkowski, F. Zoulim, K.E. Sherman, A. Alberti, and L.J. Wei Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with PegIFN-α2a and ribavirin: interim analysis of the EXTEND study [Abstract] Hepatology 52 2010 436A
17. US Food and Drug Administration. INCIVEK® (telaprevir) tablets. FDA prescribing information; May 2011. Available from: http://www.accessdata.fda. gov/drugsatfda-docs/label/2011/201917lbl.pdf. [Accessed 17.09.12].
18. European Medicines Agency. INCIVO® (telaprevir) tablets. Summary of product characteristics; July 2011. Available from: http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Product-Information/human/002313/WC500115529. pdf. [Accessed 17.09.12].
19. US Food and Drug Administration. VICTRELIS® (boceprevir) capsules. FDA prescribing information; May 2011. Available from: http://www.accessdata. fda.gov/drugsatfda-docs/label/2011/202258lbl.pdf. [Accessed 17.09.12].
20. European Medicines Agency. VICTRELIS® (boceprevir) capsules. Summary of product characteristics; July 2011. Available from: http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Product-Information/human/002332/WC500109786. pdf. [Accessed 17.09.12].
21. S. Chevaliez, C. Hézode, A. Soulier, B. Costes, M. Bouvier-Alias, and S. Rouanet High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial) Gastroenterology 141 2011 119 127
22. I.M. Jacobson, I. Catlett, P. Marcellin, N.H. Bzowej, A.J. Muir, and N. Adda Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial [Abstract] J Hepatol 54 2011 S542
23. F. Poordad, J.-P. Bronowicki, S.C. Gordon, S. Zeuzem, I.M. Jacobson, and M.S. Sulkowski IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir combination therapy [Abstract] J Hepatol 54 2011 S6
24. T. Berg, P. Andreone, S. Pol, S. Roberts, Z. Younossi, and M. Diago Predictors of virologic response with telaprevir-based combination treatment in HCV genotype 1-infected patients with prior pegylatedinterferon/ribavirin treatment failure: post-hoc analysis of the Phase III REALIZE study [Abstract] Hepatology 54 2011 375A